Henry Danahay

Henry Danahay has >20 years of drug discovery experience in the respiratory disease area and is the Head of Biology and a co-founder of Enterprise Therapeutics. Since its inception in 2015, Enterprise has focused on the development of novel therapies for the treatment of cystic fibrosis including potentiators of the calcium activated chloride channel, TMEM16A, and blockers of the epithelial sodium channel, ENaC.

Luis Galietta

Luis Galietta completed his University studies in Biology in Naples, before moving to Genova in 1986 to work as a young investigator at the Gaslini Institute, one of the largest pediatric hospitals in Europe, and at the Institute of Biophysics of the CNR. In 1991, he obtained a permanent position at the Gaslini Institute researching the molecular and functional characterization of ion transport in epithelial cells, with a special focus on the elucidation of the pathogenic mechanisms underlying cystic fibrosis lung disease and the development of possible therapeutic strategies. From 2000 to 2003, he visited the laboratory of Prof. Alan S. Verkman at the University of California San Francisco, where he worked on the identification of pharmacological modulators of the mutant CFTR protein. In 2016, he moved to the Telethon Institute of Genetics and Medicine (TIGEM) in Pozzuoli (Naples) to start a new laboratory and continue his research.

Rob Tarran

Rob Tarran is a Professor in the Department of Cell Biology and Physiology and is a member of UNC's Lineberger Cancer Center and Marsico Lung Institute. Dr Tarran received his BSc from The University of Leeds and his PhD in Physiology from Newcastle University in the UK. He completed post-doctoral research at the University of North Carolina at Chapel Hill and at the University of California at Berkley. Dr. Tarran has had over 25 years of experience in studying airway ion channels and their role in lung disease. Dr. Tarran was instrumental in developing the methodology to measure ion channel activity under native conditions seen in the lung. Over the last 5 years, he has also studied e-cigarettes and published some of the first studies on vaping in human lungs. He is currently studying the role of Ca2+ channels in lung neutrophilia.